JW Lifescience
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
JW Lifescience makes intravenous fluids, the bags of liquid solution administered directly into a patient's bloodstream in hospitals and clinics.
Its products are prescription-only medicines supplied to healthcare providers. The company's entire business is focused on this single product category, intravenous fluids, making it a specialist rather than a broad pharmaceutical company. It is listed on KOSPI, South Korea's main stock exchange.
Summary is AI-generated and may contain errors · figures from DART filings
The company is classified as a mid-sized enterprise under Korean law, placing it in a regulatory tier between a small business and a large conglomerate.
JW Lifescience in five facts
What does JW Lifescience do?
JW Lifescience makes intravenous fluids, the bags of liquid solution administered directly into a patient's bloodstream in hospitals and clinics.
Where is JW Lifescience listed and in which sector?
JW Lifescience (Korean name: JW생명과학) trades under KRX code 234080 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is JW Lifescience?
Its market capitalisation was US$126.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were JW Lifescience's latest annual revenue and operating profit?
For fiscal year 2025, JW Lifescience reported revenue of US$194.6M, operating profit of US$25.1M and net income of US$21.6M, per its annual report on DART (data retrieved from DART on 2026-09-18). Revenue was up 15.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (preliminary) (fair disclosure)
JW Lifescience filed provisional (unaudited) separate results for Q2 2026: revenue of US$40M (−0.8% year on year), operating profit of US$5.54M (+3.76% year on year) and net income of US$4.2M (−37.23% year on year).
Earnings · Aug 12 - Operating results (preliminary) (fair disclosure)
JW Lifescience filed provisional (unaudited) separate results for Q1 2026: revenue of US$39.8M (−4.48% year on year), operating profit of US$5.99M (−14.01% year on year) and net income of US$4.18M (−12.39% year on year).
Earnings · May 13 - [Amended] Cash/in-kind dividend decision
JW Lifescience updated its declared cash dividend of US$0.37 per share, equal to about 4.4% of the recent share price.
Dividend · Mar 11 · 2 versions - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Feb 2